Full Text View
Tabular View
No Study Results Posted
Related Studies
Early Access Program of the Safety of Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Active Rheumatoid Arthritis (ReAct)
This treatment has been approved for sale to the public.
Study NCT00650026   Information provided by Abbott

First Received on March 27, 2008.   Last Updated on April 10, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Additional conditions recognized in this trial
More general conditions related to this trial
Interventions listed in this trial
Additional drug interventions recognized in this trial
More general drug interventions related to this trial
Sponsors listed in this trial